Trial 13NHL-23-1


A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for Intravenous Infusion

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Biological Response Modifier, Chemotherapy: Systemic
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Ann Mohrbacher, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Mary Ordaz, D.M., Niranjan Bhatt, D.M., Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M., Jenny Kim, D.M., Aliya Anvery, Coordinator, Rhiannon Imbeah, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.